Literature DB >> 19097267

Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.

Christoph Tausch1, Peter Konstantiniuk, Franz Kugler, Roland Reitsamer, Sebastian Roka, Sabine Pöstlberger, Anton Haid.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SLNB) has become an accurate alternative to axillary lymph node dissection for early breast cancer. However, data are still insufficient as regards the combination of SLNB with preoperative chemotherapy (PC).
METHODS: The Austrian Sentinel Node Study Group investigated 167 patients who underwent SLNB and axillary lymph node dissection after 3 to 6 courses of PC. SLNB was limited to patients with a clinically negative axilla after PC. Blue dye was used in 29 cases (17%), and tracers were used in 20 (12%). A combination of the two methods was applied in most patients (n = 120; 72%).
RESULTS: At least 1 sentinel lymph node (SLN) was identified in 144 patients (identification rate, 85%): in 86% by blue dye alone, in 65% by tracers alone, and in 88% by a combination of methods. The SLN was positive in 70 women (42%) and was the only positive node with otherwise negative axillary nodes in 39 patients (23%). In 6 cases, the SLN was diagnosed as negative although tumor infiltration was detected in an upper node of the axillary basin (false-negative rate, 8%; 6 of 76 patients; sensitivity, 92%). At least 62 patients (37%) were free of tumor cells in the SLN and in the axillary nodes.
CONCLUSION: The results of SLNB after PC are comparable to the results of SLNB without PC. Further investigation in a prospective setting is warranted to confirm these promising results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19097267     DOI: 10.1245/s10434-008-0041-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.

Authors:  Maiko Takahashi; Hiromitsu Jinno; Tetsu Hayashida; Michio Sakata; Keiko Asakura; Yuko Kitagawa
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

Review 2.  Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities.

Authors:  Mohammed Keshtgar; John J Zaknun; Durre Sabih; Graciela Lago; Charles E Cox; Stanley P L Leong; Giuliano Mariani
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

3.  Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.

Authors:  Shi-Qian Lin; Nguyen-Phong Vo; Yu-Chun Yen; Ka-Wai Tam
Journal:  Ann Surg Oncol       Date:  2022-01-11       Impact factor: 5.344

4.  Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment.

Authors:  Hasan Karanlik; Neslihan Cabioglu; Adela Luciana Oprea; Ilker Ozgur; Naziye Ak; Adnan Aydiner; Semen Onder; Süleyman Bademler; Bahadir M Gulluoglu
Journal:  Breast Care (Basel)       Date:  2020-12-16       Impact factor: 2.268

Review 5.  Recent advances in the surgical care of breast cancer patients.

Authors:  Alessandra Mascaro; Massimo Farina; Raffaella Gigli; Carlo E Vitelli; Lucio Fortunato
Journal:  World J Surg Oncol       Date:  2010-01-20       Impact factor: 2.754

6.  Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.

Authors:  Guo-Chun Zhang; Ning Liao; Zi-Bai Guo; Xue-Ke Qian; Chong-Yang Ren; Meng Yao; Xue-Rui Li; Kun Wang; Jian Zu
Journal:  Clin Transl Oncol       Date:  2012-08-28       Impact factor: 3.405

7.  Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.

Authors:  Hiroyuki Takei; Takashi Yoshida; Masafumi Kurosumi; Kenichi Inoue; Hiroshi Matsumoto; Yuji Hayashi; Toru Higuchi; Sayaka Uchida; Jun Ninomiya; Kazuyuki Kubo; Hanako Oba; Shigenori Nagai; Toshio Tabei
Journal:  Int J Clin Oncol       Date:  2012-05-16       Impact factor: 3.402

8.  Ambulatory sentinel lymph node biopsy preceding neoadjuvant therapy in patients with operable breast cancer: a preliminary study.

Authors:  Shinichiro Kashiwagi; Naoyoshi Onoda; Yuka Asano; Kento Kurata; Satoru Noda; Hidemi Kawajiri; Tsutomu Takashima; Masahiko Ohsawa; Seiichi Kitagawa; Kosei Hirakawa
Journal:  World J Surg Oncol       Date:  2015-02-15       Impact factor: 2.754

9.  Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.

Authors:  Koji Takada; Shinichiro Kashiwagi; Wataru Goto; Yuka Asano; Katsuyuki Takahashi; Hisakazu Fujita; Tsutomu Takashima; Shuhei Tomita; Kosei Hirakawa; Masaichi Ohira
Journal:  J Transl Med       Date:  2018-11-19       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.